Fitzpatrick Alexander A
- SEC CIK
- 0001398595
Latest role at each company
- SPRY ARS Pharmaceuticals, Inc.Chief Legal Officeras of Jun 12, 2026
- EVFM Evofem Biosciences, Inc.General Counsel and Secretaryas of Feb 23, 2022
Trades
Every Form 4 that lists Fitzpatrick Alexander A as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Company | Filed (ET) | Trade date | Insider | Transaction | Shares | Avg price | Value | Shares after | Holding change | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| SPRYARS Pharmaceuticals, Inc. | Jun 12, 2026 | Jun 12, 2026 | Fitzpatrick Alexander AChief Legal Officer | SSaleCommon Stock | −3.36K | $10.00 | −$33.55K | 90.91K | −3.6% | SEC10b5-1 |
| SPRYARS Pharmaceuticals, Inc. | May 22, 2025 | May 20, 2025 | Fitzpatrick Alexander AChief Legal Officer | SSaleCommon Stock | −102.97K | $14.10 | −$1.45M | 89.61K | −53.5% | SEC |
| SPRYARS Pharmaceuticals, Inc. | Oct 2, 2023 | Sep 28 – Sep 29, 2023 | Fitzpatrick Alexander AChief Legal Officer | PPurchaseCommon Stock | +86.26K | $3.7058 | +$319.66K | 89.23K | +2,905.3% | SEC |
| EVFMEvofem Biosciences, Inc. | Dec 20, 20214:20 PM ET | Dec 20, 2021 | Fitzpatrick Alexander AGeneral Counsel and Secretary | PPurchaseCommon Stock | +25K | $0.389 | +$9.73K | 336.42K | +8.0% | SEC |